Ibuprofen Codeine Tablet L-Leucine Lubricant Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pharmaceutical formulations containing ibuprofen and codeine face stability issues during storage, including disintegration and adhesion problems in tablet compression processes, which affect yield and bioavailability, especially with high-dose ibuprofen formulations.
Innovation Solution
Incorporating L-leucine as a lubricant and silicified microcrystalline cellulose into the formulation to prevent adhesion and enhance stability, along with a specific diluent to active principle ratio, ensures tablets maintain hardness and dissolution rates under high-temperature and humidity conditions without compromising bioavailability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional lubricants (hydrogenated vegetable oil, insoluble carboxymethyl cellulose salts, microcrystalline cellulose) are used in tablet compression, then adhesion problems are reduced, but tablet stability during storage deteriorates (yellowing and disintegration)
Solution Approach 1:
The patent changes the chemical parameters of the lubricant by using L-leucine, an amino acid with specific chemical properties (isoelectric point, solubility characteristics) that differ from conventional lubricants. This parameter change allows the formulation to maintain both manufacturability and storage stability, as L-leucine does not cause yellowing or disintegration during storage while still providing adequate lubrication during compression.
Solution Approach 2:
L-leucine acts as an intermediary substance that mediates between the conflicting requirements of compression ease and storage stability. It provides the necessary lubricating effect during manufacturing while simultaneously serving as a stabilizing agent during storage, preventing the yellowing and disintegration issues caused by conventional lubricants.
2Quantity of substance
If high-dose ibuprofen is used in tablets, then therapeutic efficacy is improved, but adhesion to compression machine increases
Solution Approach 1:
The patent changes the formulation parameters by incorporating L-leucine at specific concentrations (1-10% w/w) in combination with high-dose ibuprofen (400-800 mg). This parameter adjustment allows the high-dose formulation to maintain adequate lubrication properties during compression, preventing adhesion to machine parts while delivering the required therapeutic dose.
Solution Approach 2:
The patent creates a composite tablet formulation combining ibuprofen, L-leucine, and other excipients in specific ratios. This composite approach allows the high-dose ibuprofen to be effectively incorporated while L-leucine provides lubricating properties that prevent adhesion issues, achieving both high efficacy and manufacturability.
3Productivity
If lubricants are added to improve compression, then manufacturing yield is improved, but adhesion to punches and matrices increases
Solution Approach 1:
The patent optimizes the concentration parameters of L-leucine in the formulation (1-10% w/w) to achieve the right balance between lubrication and adhesion prevention. This parameter optimization ensures adequate manufacturing yield while minimizing adhesion to punches and matrices, unlike conventional lubricants that require higher concentrations and still cause adhesion problems.
Solution Approach 2:
L-leucine serves as a functional lubricant that performs its adhesion-preventing function during the compression process without requiring excessive quantities or complex formulations. Its amino acid structure provides effective lubrication at lower concentrations compared to conventional lubricants, reducing both material cost and adhesion-related defects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation with L-leucine and silicified microcrystalline cellulose prevents adhesion and maintains stability, hardness, and bioavailability of ibuprofen and codeine, ensuring tablets do not disintegrate or become yellow, and maintains therapeutic activity over long-term storage.
Implementation Method 1
L-leucine, used as a lubricating excipient, prevented adhesion of the formulation to the components of the compression machine during formation of the tablets
Implementation Method 2
Incorporating L-leucine as a lubricant and silicified microcrystalline cellulose into the formulation to prevent adhesion and enhance stability
Implementation Method 3
ensures tablets maintain hardness and dissolution rates under high-temperature and humidity conditions without compromising bioavailability
Data Source
AI summary
The invention consists of a new formulation of ibuprofen and codeine in the form of a tablet, which comprises L-leucine in a concentration ranging between 4%-15% as a lubricant, in order to prevent the formulation mixture from adhering to the punches and to other elements of the compression machine during the compression process. The new formulation additionally comprises talc (0.5%-5.0%) and silicified microcrystalline cellulose (30%-80%). The formulation is preferably arranged in the form of a core that comprises the active principles and, amongst others, the L-leucine, part of the talc and the silicified microcrystalline cellulose; this core is coated with a composition that contains a copolymer of methacrylic acid and ethyl acrylate. The tablets of the invention do not exhibit flaking problems, have an adequate hardness with a convenient attrition to allow for subsequent coating, offer disintegration values of less than 5 minutes, with dissolution values for both active principles in accordance with those specified for rapid-release tablets.